Penn Medicine researchers are continuing their work in trying to understand the mechanisms through which anesthetics work to elicit the response that puts millions of Americans to sleep for surgeries each day.
Scientists win $3.3M grant to accelerate treatment development for intellectual disability, autism, epilepsyApril 2, 2015 3:40 pm | by The Scripps Research Institute | News | Comments
Scientists from the Florida campus of The Scripps Research Institute have been awarded $3.3...
Animal study shows that a nanoparticle applied at the time of surgery slowly releases needed...
Scientists have extensive knowledge of how mutations of single genes during evolution can have a fitness cost or benefit for the host organism. However, genes are often embedded into complex regulatory networks. The role of these gene networks in evolution is less well understood.
Imagine being able to identify people likely to develop a particular disease - and then stop it before it starts.
Ten years after the 2005 Paris Declaration on Aid Effectiveness reported on the need for better coordination in the global fight against disease, global pharmaceutical supply chains remain fragmented and lack coordination, facing at least 10 fundamental challenges, according to a newly published paper.
Swiss researchers have suspended the testing of one of the leading Ebola vaccine candidates after some volunteers reported unexpected side effects.
A group of scientists in Florida have combined medicine and advanced nanotechnological engineering to create a smarter, more targeted therapy that could overcome the most lethal gynecologic cancer. The technology involves combining Taxol, a chemotherapy drug, with magneto-electric nanoparticles that can penetrate the blood-brain barrier.
The 2nd Annual Pharma Data Analytics Conference will enable senior-level analytics professionals to improve the bottom line of their business through utilizing the potential of big data. Driven by single-track case study presentations from Pfizer, Celgene, Novartis, Merck and many others, this program will explore recent trends in the pharmaceutical environment, including the influence of analytics in the commercial space, data visualization tools and techniques and methodologies for forecasting across multiple business units.
German drug company Merck says it has agreed to buy St. Louis-based chemical firm Sigma-Aldrich Corp. for $17 billion in a deal Merck says will strengthen its business in chemicals and laboratory equipment. Sigma-Aldrich has over 9,000 employees in 40 countries and supplies chemicals and laboratory equipment to government and commercial facilities. Its board of directors has unanimously approved the deal.
According to recent research in the U.K. , use of electronic health records to understand the best available treatment for patients, from a range of possible options, is more efficient and less costly for taxpayers than the existing clinical trial process.
Agilent Technologies Inc. has announced the signing of a memorandum of understanding with Seoul National Univ., Korea's top research university, on a new research center that will support the College of Pharmacy's New Drug Development Center. The collaboration will conduct drug metabolism studies, develop new compounds, study remedial effects and toxicity, assess pharmacokinetics, and conduct clinical tests for drugs.
AMSBIO has announced the launch of ClioCell, an ex vivo device for removal of dying and dead cells, improving viability and quality of cell populations and their subsequent productivity. The system comprises super-paramagnetic nanoparticles which have been coupled with proprietary elements that bind to dead and dying cells and cell debris.
Scientists in the U.K. have proposed a new computer-based method of screening drugs that could be used to slow the aging process in humans. The proposed method uses gene expression data from “young” and “old” tissues to construct the cloud of molecular signalling pathways involved in ageing and longevity. It then evaluates the effects of a large number of drugs and drug combinations to emulate a youthful state for cells and tissues.
Over the past 20 years, the number of laboratory tests available to primary care physicians has doubled, to more than 3,500 tests, and physicians are challenged by the quantity of tests available. A recent survey conducted by the U.S. Centers for Disease Control and Prevention suggests they often face uncertainty in ordering and interpreting clinical laboratory tests, and would welcome better electronic clinical decision support tools.
In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.
Drugmaker Merck & Co. is joining two dozen other pharmaceutical companies and contract laboratories in committing to not use chimpanzees for research. The growing trend could mean roughly 1,000 chimps in the U.S. used for research or warehoused for many years in laboratory cages could be "retired" to sanctuaries by around 2020.
A team of researchers has uncovered critical information that could help scientists understand how protein polymers interact with other self-assembling biopolymers. The research helps explain naturally occurring nanomaterial within cells and could one day lead to engineered bio-composites for drug delivery, artificial tissue, bio-sensing, or cancer diagnosis.
Univ. of Michigan researchers are the first to use brain imaging procedures to track the clinical action of pregabalin, a drug known by the brand name Lyrica that is prescribed to patients suffering from fibromyalgia and neuropathic pain. The study suggests role of brain imaging in creating personalized treatment of chronic pain.
Accelrys Inc. has announced the release of Accelrys Insight and Accelrys Insight for Excel, completing the roll-out of Accelrys’ next-generation cheminformatics suite and providing an interactive, collaborative environment for rapid and effective decision-making in drug discovery.
According to a recent study published by the National Science Foundation (NSF), businesses spent more on research and development (R&D) in 2011 than they did in 2010. The figures revealed that during 2011, companies in manufacturing industries performed $201 billion, or 68%, of domestic R&D.
A study at the Univ. of Utah finds that more than 60% of antibiotic prescriptions are for types that kill multiple kinds of bacteria. Unfortunately, in more than 25% of cases such prescriptions are useless because the infection stems from a virus, which cannot be treated with antibiotics. This overuse of antibiotics has a number of downsides.
Researchers in Texas have discovered a new chemical reaction that has the potential to lower the cost and streamline the manufacture of compounds ranging from agricultural chemicals to pharmaceutical drugs. The reaction resolves a long-standing challenge in organic chemistry in creating phenolic compounds from aromatic hydrocarbons quickly and cheaply.
On Thursday, Sigma-Aldrich Corp.announced a partnership with The Scripps Research Institute (TSRI) to fund research and provide immediate, day-of-publication access to TSRI researchers’ discoveries for the synthesis and analysis of potential drugs. The partnership promises to eliminate months from the translation of cutting-edge chemistry into widespread applications for drug discovery.
British drugmaker GlaxoSmithKline PLC said Wednesday that it will buy Okairos AG for about $323 million, gaining the Swiss vaccine developer's products. GlaxoSmithKline said Okairos is studying vaccine technology that could be used in shots that can both prevent and cure infections or diseases.
Specialty drugmaker Biogen Idec said Tuesday it submitted a new injectable multiple sclerosis drug to the Food and Drug Administration for U.S. market approval. The drug, called Plegridy, is intended to treat patients with relapsing forms of multiple sclerosis.
Shares of XenoPort Inc. sank Monday after the drug developer said a potential treatment for multiple sclerosis patients failed in late-stage clinical testing, and it will stop developing the drug. The Santa Clara, Calif., company said the treatment, labeled arbaclofen placarbil, failed to show a statistically significant improvement for patients taking it compared to a fake drug.
Bristol-Myers Squibb Co. said Friday that U.S. regulators expanded approval of its HIV drug Sustiva to children as young as three months old. The capsule-based drug was first approved in 1998 to treat HIV-infected children who are age three and older and weigh at least 22 pounds. The new approval expands the drug's use to children age three months to three years who weigh at least 7.7 pounds.
- Page 1